Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line

2.

Durie

BGM

,

Hoering

A

,

Sexton

R

, et al.

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

.

Blood Cancer J

.

2020

;

10

(

5

):

53

.

doi:10.1038/s41408-020-0311-8

.

3.

Durie

BGM

,

Hoering

A

,

Abidi

MH

, et al.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

.

Lancet

.

2017

;

389

(

10068

):

519

-

527

.

doi:10.1016/S0140-6736(16)31594-X

.

4.

Chari

A

,

Kaufman

JL

,

Laubach

JP

.

et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): final analysis of griffin among clinically relevant subgroups

.

Blood

.

2022

;

140

(

suppl 1

):

7278

-

7281

.

doi:10.1182/blood-2022-162339

.

5.

Sonneveld

P

,

Broijl

A

,

Gay

F

, et al.

Bortezomib, lenalidomide, and dexamethasone (VRd)±daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS)

.

J Clin Oncol

.

2019

;

37

(

15 suppl

):

TPS8055

.

doi:10.1200/JCO.2019.37.15_suppl.TPS8055

.

6.

Moreau

P

,

Hulin

C

,

Perrot

A

, et al.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2021

;

22

(

10

):

1378

-

1390

.

7.

Mateos

MV

,

Cavo

M

,

Blade

J

, et al.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

.

Lancet

.

2020

;

395

(

10218

):

132

-

141

.

8.

Goldschmidt

H

,

Mai

EK

,

Bertsch

U

, et al;

German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators

.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active- controlled, phase 3 trial

.

Lancet Haematol

.

2022

;

9

(

11

):

e810

-

e821

.

doi:10.1016/S2352-3026(22)00263-0

.

9.

Dimopoulos

MA

,

Terpos

E

,

Boccadoro

M

, et al.

Subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): overall survival results from the phase 3 Apollo study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

7272

-

7274

.

10.

Usmani

SZ

,

Quach

H

,

Mateos

M-V

, et al.

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

.

Blood Adv

.

2023

;

7

(

14

):

3739

-

3748

.

11.

Dimopoulos

MA

,

Goldschmidt

H

,

Niesvizky

R

, et al.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2017

;

18

(

10

):

1327

-

1337

.

12.

Leleu

X

,

Martin

T

,

Weisel

K

, et al.

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

.

Ann Hematol

.

2022

;

101

(

10

):

2123

-

2137

.

doi:10.1007/s00277-022-04917-5

.

13.

Lammerts van Bueren

J

,

Jakobs

D

,

Kaldenhoven

N

, et al.

Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79

.

Blood

.

2014

;

124

(

21

):

3474

.

doi:10.1182/blood.V124.21.3474.3474

.

14.

Mikhael

J

,

Belhadj-Merzoug

K

,

Hulin

C

, et al.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

.

Blood Cancer J

.

2021

;

11

(

5

):

89

.

doi:10.1038/s41408-021-00478-4

.

15.

Moreau

P

,

Dimopoulos

M-A

,

Mikhael

J

, et al;

IKEMA study group

.

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

.

Lancet

.

2021

;

397

(

10292

):

2361

-

2371

.

doi:10.1016/S0140-6736(21)00592-4

.

16.

Martin

T

,

Dimopoulos

M-A

,

Mikhael

J

, et al.

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study

.

Blood Cancer J

.

2023

;

13

(

1

):

72

.

doi:10.3389/fonc.2020.624661

.

17.

Dolph

M

,

Tremblay

G

,

Leong

H.

Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated multiple myeloma (MM) based on results from the phase III BOSTON trial

.

Pharmacoeconomics

.

2021

;

39

(

11

):

1309

-

1325

.

doi:10.1007/s40273-021-01068-9

.

18.

Grosicki

S

,

Simonova

M

,

Spicka

I

, et al.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

.

Lancet

.

2020

;

396

(

10262

):

1563

-

1573

.

doi:10.1016/S0140-6736(20)32292-3

.

19.

Podar

K

,

Shah

J

,

Chari

A

,

Richardson

PG

,

Jagannath

S.

Selinexor for the treatment of multiple myeloma

.

Expert Opin Pharmacother

.

2020

;

21

(

4

):

399

-

408

.

doi:10.1080/14656566.2019.1707184

.

20.

Vogl

DT

,

Dingli

D

,

Cornell

RF

, et al.

Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM Study

.

Blood

.

2016

;

128

(

22

):

491

.

doi:10.1182/blood.V128.22.491.491

.

21.

Nooka

AK

,

Costa

LJ

,

Gasparetto

CJ

, et al.

Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable

.

Clin Lymphoma Myeloma Leuk

.

2022

;

22

(

7

):

e526

-

e531

.

doi:10.1016/j.clml.2022.01.014

.

22.

Sonneveld

P

,

Zweegman

S

,

Cavo

M

, et al.

Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with first progression of multiple myeloma refractory to bortezomib and lenalidomide. Final report of the EMN011/HOVON114 trial [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

1664

.

23.

Moreau

P

,

Masszi

T

,

Grzasko

N

, et al.

Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma

.

N Engl J Med

.

2016

;

374

(

17

):

1621

-

1634

.

24.

Lonial

S

,

Dimopoulos

M

,

Palumbo

A

, et al.

Elotuzumab therapy for relapsed or refractory multiple myeloma

.

N Engl J Med

.

2015

;

373

(

7

):

621

-

631

.

25.

Perrot

A

,

Lauwers-Cances

V

,

Cazaubiel

T

, et al.

Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial

.

Blood

.

2020

;

136

(

suppl 1

):

39

.

26.

Richardson

PG

,

Jacobus

SJ

,

Weller

EA

, et al;

DETERMINATION Investigators

.

Triplet therapy, transplantation, and maintenance until progression in myeloma

.

N Engl J Med

.

2022

;

387

(

2

):

132

-

147

.

doi:10.1056/NEJMoa2204925

.

27.

Markham

A.

Belantamab mafodotin: first approval

.

Drugs

.

2020

;

80

(

15

):

1607

-

1613

.

doi:10.1007/s40265-020-01404-x

.

28.

Eastman

S

,

Shelton

C

,

Gupta

I

,

Krueger

J

,

Blackwell

C

,

Bojczuk

PM

.

Synergistic activity of belantamab mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-expressing cancer cell lines

.

Blood

.

2019

;

134

(

suppl 1

):

4401

.

doi:10.1182/blood-2019-123705

.

29.

Montes de Oca

R

,

Alavi

AS

,

Vitali

N

, et al.

Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo

.

Mol Cancer Ther

.

2021

;

20

(

10

):

1941

-

1955

.

doi:10.1158/1535-7163.MCT-21-0035

.

30.

Lonial

S

,

Lee

HC

,

Badros

A

, et al.

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

.

Cancer

.

2021

;

127

(

22

):

4198

-

4212

.

doi:10.1002/cncr.33809

.

31.

Wahab

A

,

Rafae

A

,

Mushtaq

K

, et al.

Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma

.

Front Oncol

.

2021

;

11

:

678634

.

doi:10.3389/fonc.2021.678634

.

32.

GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma

.

News release. GlaxoSmithKline

;

2022

.

33.

BLENREP (belantamab mafodotin): EU summary of product characteristics

.

European Medicines Agency (EMA)

.

34.

Munshi

NC

,

Anderson

LD

Jr,

Shah

N

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

-

716

.

doi:10.1056/NEJMoa2024850

.

35.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

-

324

.

doi:10.1016/S0140-6736(21)00933-8

.

36.

Kang

C.

Teclistamab: first approval

.

Drugs

.

2022

;

82

(

16

):

1613

-

1619

.

doi:10.1007/s40265-022-01793-1

.

37.

San-Miguel

J

,

Dhakal

B

,

Yong

K

, et al.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

.

N Engl J Med

.

2023

;

389

(

4

):

335

-

347

.

doi:10.1056/NEJMoa2303379

.

38.

Rodriguez-Otero

P

,

Ailawadhi

S

,

Arnulf

B

, et al.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2023

;

388

(

11

):

1002

-

1014

.

doi:10.1056/NEJMoa2213614

.

39.

Simmons

GL

,

Castaneda Puglianini

O.

T-cell-based cellular immunotherapy of multiple myeloma: current developments

.

Cancers (Basel)

.

2022

;

14

(

17

).

40.

Dytfeld

D

,

Dhakal

B

,

Agha

M

, et al.

Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5) [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

1835

.

41.

Usmani

S

,

Patel

K

,

Hari

P

, et al.

KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

875

-

877

.

42.

Usmani

SZ

,

Berdeja

JG

,

Truppel-Hartmann

A

, et al.

KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma [abstract]

.

Blood

.

2020

;

136

(

suppl 1

):

18

-

19

.

43.

Raje

NS

,

Berdeja

JG

,

Rodriguez-Otero

P

, et al.

KarMMa-7, a phase 1/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed/refractory multiple myeloma (RRMM) [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

4830

.

44.

Sebag

M

,

Raje

NS

,

Bahlis

NJ

, et al.

Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetismm-1 [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

895

.

45.

Lesokhin

AM

,

Tomasson

MH

,

Arnulf

B

, et al.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

.

Nat Med

.

2023

;

29

(

9

):

2259

-

2267

.

46.

Landgren

O

,

Kazandjian

D

,

O’Connell

A

,

Finn

G

,

Raje

N.

Magnetismm-4: an open label, phase 1B/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

10172

-

10173

.

47.

Grosicki

S

,

Crafoord

J

,

Koh

Y

, et al.

MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2022

;

40

(

16 suppl

):

tps8074

.

doi:10.13039/100004319

.

48.

Mateos

MV

,

Bahlis

NJ

,

Costa

LJ

, et al.

MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2022

;

40

(

16 suppl

):

TPS8072

.

doi:10.1200/JCO.2022.40.16_suppl.TPS8072

.

49.

Dholaria

BR

,

Weisel

K

,

Mateos

M-V

, et al.

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated TRIMM-2 results [abstract]

.

J Clin Oncol

.

2023

;

41

(

16 suppl

):

8003

.

50.

Cohen

YC

,

Morillo

D

,

Gatt

ME

, et al.

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM) [abstract]

.

J Clin Oncol

.

2023

;

41

(

16 suppl

):

8002

.